Somamers

Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.

Under the agreement, BMS has access to the 1,310 reagents in the public version of SomaLogic's SOMAscan assay along with a number of custom-developed reagents.

Proteomics diagnostics firm Somalogic reported data this week supporting the utility of its blood-based 13-protein panel for the detection of malignant mesothelioma.

By Adam Bonislawski
Somalogic last week published in PLoS One a study offering the first data on use of its aptamer-based Somascan platform in tissue samples.

SomaLogic will provide New England Biolabs with protein-binding reagents for use in NEB's nucleic acid amplification and PCR products.

SomaLogic will supply NEB with certain of its SomaMers technology to be incorporated into NEB's products as reversible inhibitors of thermally active DNA polymerases used in PCR.

Anticipating that NGS will become a key clinical tool in coming years, several proteomics firms and researchers are investigating it as a platform for protein biomarker detection assays that use nucleotides as capture agents, hoping to take advantage of the technology's precision and multiplexing ability.

The trials will evaluate biomarker panels for lung, colon, and prostate cancer, and may include a comparison of proteomics-based lung cancer tests from Somalogic and Celera.

Pages

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.